55 East Monroe Street
Suite 3300
Chicago, Illinois 60603-5792

J&J Said to Agree to Pay $1 Billion in Risperdal Marketing Probe

January 5, 2012
Bloomberg

Johnson & Johnson (JNJ) will pay more than $1 billion to the U.S. and most states to resolve a civil investigation into marketing of the antipsychotic Risperdal, according to people familiar with the matter.

J&J, the world’s largest health products company, reached an agreement last week with the U.S. attorney in Philadelphia, according to the people, who weren’t authorized to speak about the matter. Negotiations over a possible criminal plea are still under way, they said.

The U.S. government has been investigating Risperdal sales practices since 2004, including allegations the company marketed the drug for unapproved uses, J&J has said in Securities and Exchange Commission filings (JNJ). The company said it has been in negotiations with the U.S. to settle the investigation. To read the complete article click here.

Attorneys at law

 

resources

False claims act basics

Newsroom

Our successes

Our website uses cookies to improve your experience. By continuing to use this website, you are agreeing to our Cookie Policy.